You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Ibrutinib Intolerance

Showing 1 - 25 of 1,314
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma Trial in New York, Columbus (Ibrutinib)

Active, not recruiting
  • T-cell Lymphoma
  • Relapsed and Refractory T-cell Lymphoma
  • New York, New York
  • +1 more
Nov 8, 2022

Mantle Cell Lymphoma Trial in Houston (Acalabrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Aug 22, 2022

Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI (Duvelisib, Ibrutinib)

Terminated
Has Results
  • Small Lymphocytic Leukemia (SLL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 15, 2022

Hepatitis, Safety and Tolerability Trial run by the NHLBI (HEPLISAV-B)

Completed
Has Results
  • Hepatitis
  • Safety and Tolerability
  • HEPLISAV-B
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 13, 2022

Relapsed or Refractory Chronic Lymphocytic Leukemia Trial in France (Ibrutinib, Daratumumab)

Recruiting
  • Relapsed or Refractory Chronic Lymphocytic Leukemia
  • Annecy, France
  • +22 more
Jun 28, 2021

Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI

Active, not recruiting
Has Results
  • Safety and Tolerability
  • +3 more
  • Zoster Vaccine Recombinant, Adjuvanted
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 10, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Lymphoma Trial (Ibrutinib, Venetoclax)

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Small Lymphocytic Lymphoma
  • (no location specified)
Jul 19, 2023

Cardiovascular Complications of Ibrutinib Therapy

Not yet recruiting
  • Ibrutinib Treatment
  • ophthalmological examination
  • blood test
  • Dijon, France
    Chu Dijon Bourgogne
Jul 3, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • (no location specified)
Nov 22, 2023

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (Durvalumab, Lenalidomide, Rituximab)

Active, not recruiting
Has Results
  • Lymphoma
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Gilbert, Arizona
  • +53 more
Jan 25, 2022

Glioblastoma Trial in Cleveland (Ibrutinib, Radiation, Temozolomide (TMZ))

Active, not recruiting
  • Glioblastoma
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jan 30, 2023

Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy Trial in United States (Emavusertib, ibrutinib)

Recruiting
  • Relapsed Hematologic Malignancy
  • Refractory Hematologic Malignancy
  • Phoenix, Arizona
  • +10 more
Feb 1, 2023

Chronic Lymphocytic Leukemia Trial in Spain (Ibrutinib 140 MG Oral Capsule [Imbruvica])

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Ibrutinib 140 MG Oral Capsule [Imbruvica]
  • Palma De Mallorca, Illes Balears, Spain
  • +19 more
Sep 15, 2022

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage IV Follicular Lymphoma Trial in

Recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +5 more
  • Fresno, California
  • +2 more
Jan 24, 2023

Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7 Trial in Rochester (drug,

Active, not recruiting
  • Metastatic Melanoma
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 13, 2023

Mantle Cell Lymphoma Trial in Houston (Ibrutinib)

Recruiting
  • Mantle Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Nov 1, 2022

Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Asymptomatic COVID-19 Infection Laboratory-Confirmed, B-Cell Tumor, Chronic Lymphocytic Leukemia Trial in Rochester (Ibrutinib,

Withdrawn
  • Asymptomatic COVID-19 Infection Laboratory-Confirmed
  • +8 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 2, 2022

Unfit CLL Included in GIMEMA LLC1114 Trial Who Discontinued

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Observation
  • (no location specified)
Oct 12, 2023

Hematopoietic and Lymphoid Cell Tumor, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in

Not yet recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jul 10, 2022

CNS B-Cell Non-Hodgkin Lymphoma, Recurrent CNS Lymphoma, Refractory CNS Lymphoma Trial in Houston (Ibrutinib, Nivolumab)

Recruiting
  • Central Nervous System B-Cell Non-Hodgkin Lymphoma
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Chronic Lymphocytic Leukemia Trial in Lebanon (BNC105P, Ibrutinib)

Completed
  • Chronic Lymphocytic Leukemia
  • BNC105P
  • Ibrutinib
  • Lebanon, New Hampshire
    Dartmouth-Hitchcock Medical Center
Jan 3, 2023

Lymphoma, Mantle-Cell Trial in Worldwide (Ibrutinib, Lenalidomide, Rituximab)

Recruiting
  • Lymphoma, Mantle-Cell
  • Barretos, Brazil
  • +150 more
Jan 27, 2023

Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in Houston (drug,

Active, not recruiting
  • Prolymphocytic Leukemia
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

Chronic Lymphocytic Leukemia Trial in Houston (Ibrutinib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Sep 21, 2022